Toxic shock syndrome toxin

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Lunedì, Novembre 14, 2022
Breast, Blood, Administration, EGFR, TCR, Telephone, Biotechnology, Poster, Toxic shock syndrome toxin, Risk, Research and development, KRAS, Mutation, Therapy, TP53, Conference, SITC, Research, Investigational New Drug, Safety, Progression-free survival, Security (finance), Society, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ID, Intellectual property, Hlas, Development, Cash, State Administrative Expenses, NSCLC, Receptor, National Cancer Institute, Immunotherapy, Colorectal cancer, Food, Patient, Sleeping Beauty, Pharmaceutical industry, Vaccine

Third Quarter Ended September 30, 2022 Financial Results

Key Points: 
  • Third Quarter Ended September 30, 2022 Financial Results
    Collaboration Revenue: Collaboration revenue was $2.9 million for the third quarter of 2022, compared to $0.4 million for the third quarter of 2021, an increase of 631%.
  • Research and Development Expenses: Research and development expenses were $7.9 million for the third quarter of 2022, compared to $14.5 million for the third quarter of 2021, a decrease of approximately 46%.
  • Cash and Cash Equivalents: As of September 30, 2022, Alaunos had approximately $37.8 million in cash and cash equivalents and restricted cash of $13.9 million.
  • Operating cash burn for the third quarter of 2022 was $6.1 million compared to $9.6 million in the third quarter of 2021, a decrease of $3.4 million or 36%.

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Sabato, Settembre 10, 2022
Pharmacokinetics, Terminology, NASDAQ, Toxic shock syndrome toxin, Population, Mouse, PRAME, Half-life, Clinical trial, Oncology, Toxicity, Trial of the century, Congress, Cancer, Cytokine release syndrome, SEC, HLA, European Society of Gene and Cell Therapy, Nature, LinkedIn, European Society for Medical Oncology, ESMO, Safety, TCR, Adoptive cell transfer, Forward-looking statement, Patient, Neoplasm, Twitter, Fine chemical, Pharmaceutical industry, Vaccine, Instagram

Immatics TCER molecules are "off-the-shelf"TCR Bispecifics engineered with two binding regions: a TCR domain and a T cell recruiter domain.

Key Points: 
  • Immatics TCER molecules are "off-the-shelf"TCR Bispecifics engineered with two binding regions: a TCR domain and a T cell recruiter domain.
  • The promising preclinical results for our next-generation, half-life extended TCER IMA402 reflect the potential of our TCR Bispecific approach for patients with solid tumors, commented Carsten Reinhardt, M.D., Ph.D., Chief Development Officer at Immatics.
  • We look forward to initiating the IMA402 Phase 1/2 clinical trial in 2023 as part of our strategy to tackle PRAME with two distinct therapeutic modalities.
  • HLA-A*02:01-positive patients with different solid tumors expressing PRAME will initially receive weekly infusions of IMA402.

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers

Retrieved on: 
Lunedì, Agosto 22, 2022
HLA, COVID-19, Breast, Glioblastoma, Lymphatic system, Safety, Securities Exchange Act of 1934, Cancer, Securities Act of 1933, Autoimmune disease, Research, Regulatory T cell, Time, Immunoglobulin G, Risk, AML, Toxic shock syndrome toxin, Result, WT1, Board, PMHC cellular microarray, Drug Quality and Security Act, Policy, Food, Conversation, Lung, Patent, Form 10-Q, GLOBE, Patient, FC, Board of directors, Nasdaq, FDA, Selective, Financial condition report, APC, Annual report, Analysis, Forward-looking statement, Trial of the century, TCR, Pharmaceutical industry, Vaccine

The study will initially focus on colorectal, gastric, pancreatic, and ovarian cancers.

Key Points: 
  • The study will initially focus on colorectal, gastric, pancreatic, and ovarian cancers.
  • Patients with WT1-expressing cancers, and those with recurrent metastatic disease, represent an important unmet clinical need and underscore the opportunity for this promising new therapeutic.
  • WT1 is a well-recognized onco-fetal protein known to be over-expressed in several cancers, including solid tumors and hematologic malignancies.
  • This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in selective T cell modulation.

Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80

Retrieved on: 
Lunedì, Giugno 6, 2022
Oncology, Health, Research, Science, Pharmaceutical, Cardiology, Biotechnology, TCR, MSK, Company, Memorial Sloan Kettering Cancer Center, Melanoma, HLA, NDC80, CEO, CAR, Cancer, AML, Blood, Toxic shock syndrome toxin, Lymphoma, Therapy, FDA, Red blood cell, Patient, Stem cell, Antibody, Lymphatic system, ALL, Protein, Mesothelioma, Neoplasm, Pharmaceutical industry, Vaccine, San Francisco Bay Area

Chimeric antigen receptor (CAR) T cells represent a novel class of FDA-approved drugs with high efficacy against refractory B cell-derived malignancies.

Key Points: 
  • Chimeric antigen receptor (CAR) T cells represent a novel class of FDA-approved drugs with high efficacy against refractory B cell-derived malignancies.
  • In the study, anti-NDC80 TCRm-redirected T cells demonstrated high specificity in recognizing and killing multiple cancer cell lines.
  • We are excited by the study and look forward to seeing the expanded use of TCR mimic antibodies in other cancer types.
  • Eureka Therapeutics, Inc. is a privately-held clinical-stage biotechnology company focusing on developing novel T cell therapies to treat cancers.

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Retrieved on: 
Martedì, Maggio 10, 2022
Head, PRAME, Forward-looking statement, Population, Adoptive cell transfer, Instagram, Twitter, NASDAQ, Pharmacokinetics, Neoplasm, Safety, Prevalence, HNSCC, Patient, Cytokine release syndrome, Trial of the century, Bristol Myers Squibb, Half-life, Clinical trial, Program, MTD, Cancer, MAGEA4, NCT, Sarcoma, LinkedIn, TCR, HLA, SCLC, Index (publishing), SEC, Terminology, Squamous cell carcinoma, Toxic shock syndrome toxin, Melanoma, Nature, Pharmaceutical industry, Vaccine

IMA401 is the most advanced product candidate from Immatics TCR Bispecific pipeline targeting an HLA-A*02-presented peptide derived from both MAGEA4 and MAGEA8.

Key Points: 
  • IMA401 is the most advanced product candidate from Immatics TCR Bispecific pipeline targeting an HLA-A*02-presented peptide derived from both MAGEA4 and MAGEA8.
  • Secondary objectives are to characterize safety and tolerability, evaluate initial anti-tumor activity and assess pharmacokinetics of IMA401.
  • The Phase 1 trial consists of a dose-escalation (Phase 1a) portion that will be followed by a dose-expansion (Phase 1b) portion to treat patients at the recommended dose level.
  • Our TCER IMA401 could treat a range of solid tumors and therefore meet currently unmet needs of a broad patient population.

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Venerdì, Aprile 8, 2022
Differentiable function, Cancer, Therapy, Epitope, TCR, Cell death, Molecular medicine, Patient, Oncogene, KRAS, Mouse, AACR, Hlas, American Association, Neoplasm, Allele, Cancer/testis antigens, Berlin, Association, American Association for Cancer Research, Technology, Annual general meeting, GLOBE, Toxic shock syndrome toxin, HLA, CD8, Max, SAN, Maintenance, Peptide, Toxicity, Immunization, Vaccine

This is an eventful year for T-knife, filled with meaningful corporate milestones, stated Thomas M. Soloway, Chief Executive Officer of T-knife.

Key Points: 
  • This is an eventful year for T-knife, filled with meaningful corporate milestones, stated Thomas M. Soloway, Chief Executive Officer of T-knife.
  • These TCRs mediated recognition of a large panel of KRASG12V-expressing cancer cell lines, as demonstrated by cytokine responses and cytotoxicity.
  • KRAS mutations are defined as driver mutations, meaning they are responsible for both the initiation and maintenance of cancer.
  • Targeting driver mutations reduces the potential for the tumor to employ immune escape mechanisms, making the KRAS family an ideal target for TCR-T therapy.

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

Retrieved on: 
Mercoledì, Febbraio 16, 2022
Deutsch, Millipore, Angiotensin, Tissue, Systematic review, Merck, Company, Journal, PCT, Toxic shock syndrome toxin, OTCQB, ACE2, Blood, Vaccine, RNA transfection, Hematology-Oncology and Stem Cell Transplantation Research Center, Report, Gastrointestinal tract, Platelet factor 4, DNP, COVID-19 vaccine, Liver, Myocardial infarction, FRA, Angiotensin-converting enzyme 2, CDMO, Ohio State University, RBD, Myocarditis, Mouse, CSE, Pericarditis, Severe acute respiratory syndrome coronavirus 2, COVID-19, Epithelium, Thrombosis, II, Heart, Pharmaceutical industry, BC

VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor. The finding suggests that the Company's haptenized SARS-CoV-2 spike protein vaccine may not lead to the unusual but serious myocarditis observed with mRNA vaccines. Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.

Key Points: 
  • Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • The Biovaxys vaccine for Covid-19, BVX-0320, comprises a portion of the SARS-CoV-2 spike protein that is modified by the hapten, dinitrophenyl (DNP); hapten modification prevents ACE2 binding while retaining immunogenicity.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

Retrieved on: 
Mercoledì, Febbraio 16, 2022
Deutsch, Millipore, Angiotensin, Tissue, Systematic review, Merck, Company, Journal, PCT, Toxic shock syndrome toxin, OTCQB, ACE2, Blood, Vaccine, RNA transfection, Hematology-Oncology and Stem Cell Transplantation Research Center, Report, Gastrointestinal tract, Platelet factor 4, DNP, COVID-19 vaccine, Liver, Myocardial infarction, FRA, Angiotensin-converting enzyme 2, CDMO, Ohio State University, RBD, Myocarditis, Mouse, CSE, Pericarditis, Severe acute respiratory syndrome coronavirus 2, COVID-19, Epithelium, Thrombosis, II, Heart, Pharmaceutical industry, BC

VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor. The finding suggests that the Company's haptenized SARS-CoV-2 spike protein vaccine may not lead to the unusual but serious myocarditis observed with mRNA vaccines. Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.

Key Points: 
  • Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • The Biovaxys vaccine for Covid-19, BVX-0320, comprises a portion of the SARS-CoV-2 spike protein that is modified by the hapten, dinitrophenyl (DNP); hapten modification prevents ACE2 binding while retaining immunogenicity.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.

IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19

Retrieved on: 
Mercoledì, Febbraio 9, 2022
SAD, IGM, Patient, Industry, GLOBE, Intellectual property, Variant, U.S. Securities and Exchange Commission, Immunoglobulin G, Doctor of Philosophy, MAD, Immune system, IC50, Voi, Risk, Toxic shock syndrome toxin, Immunoglobulin M, Safety, Security (finance), Pharmacokinetics, Severe acute respiratory syndrome coronavirus 2, SEC, Therapy, Nasdaq, Lists of World Heritage Sites, Infection, MD, RBD, Antibody, 5-carboxymethyl-2-hydroxymuconate Delta-isomerase, COVID-19, Pharmaceutical industry, Vaccine, Omicron, Nature, Delta, VOC

MOUNTAIN VIEW, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its progress in two Phase 1 clinical trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, for the treatment and prevention of COVID-19. The first, a Phase 1 clinical trial in the U.S., is a multi-center, randomized, double-blinded, placebo-controlled single (SAD) and multiple (MAD) ascending dose study to assess the safety, tolerability, and pharmacokinetics of IGM-6268 administered intranasally in healthy volunteers. The first two dose cohorts of healthy volunteers have been successfully cleared in the U.S., and data from the study are expected in the first half of 2022. The second, a Phase 1a/1b clinical trial in South Africa, is a multi-center, randomized, double-blinded, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of IGM-6268 administered intranasally first in healthy volunteers, once an appropriate dose cohort has been cleared, in outpatients with mild to moderate COVID-19. The first dose cohort of healthy volunteers has been cleared in the South Africa study, and data from the study are expected in mid-2022.

Key Points: 
  • IGM-6268 is an engineered IgM antibody that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
  • Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.
  • Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies.
  • Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Venerdì, Novembre 12, 2021
Biotechnology, Health, Oncology, Clinical Trials, Health, SITC, Intelligence, STAT, Cancer, ATP, List of life sciences, Toxic shock syndrome toxin, Immunoglobulin G, Immune system, Society for Immunotherapy of Cancer, NK, CD25, NKT, Annual general meeting, Therapy, Toxicity, Immunotherapy, Immunosuppression, Pulmonary edema, Phosphorylation, Vaccine

Data were presented in a poster presentation at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Data were presented in a poster presentation at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • Supported by these data, we are continuing to advance AU-007 into a Phase 1/2 clinical trial.
  • Aulos Bioscience presented data at SITC establishing both the specificity and activity of AU-007.
  • Aulos Bioscience is an immuno-oncology company working to revolutionize cancer patient care through best-in-class IL-2 therapeutics that direct patients own immune systems toward killing tumor cells.